ACCC President Reignites Resilience in Oncology Caregivers

April 25th 2025

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates and durable responses vs chemotherapy alone.

Jordyn Sava;Aditya Bardia, MD, MPH

February 6th 2025

FDA Oks Penpulimab for First-Line Non-Keratinizing Nasopharyngeal Carcinoma

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

The FDA has approved penpulimab with chemotherapy for first-line recurrent/metastatic non-keratinizing nasopharyngeal carcinoma and alone after prior treatment.

Jordyn Sava;Sanjay K. Juneja, MD

January 15th 2025

FDA Clears Phase 1 Study of TGW101 for Advanced Solid Tumor Treatment

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

SUNLIGHT Trial Defines CRC in the Refractory Setting

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum tolerated dose in up to 50 patients.

$SUNLIGHT Trial Defines CRC in the Refractory Setting$

Positive Outcomes Confirmed for Frontline ICI Use in Metastatic CRC

Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: trifluridine/tipiracil and regorafenib.

Related Content

April 25th 2025

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates and durable responses vs chemotherapy alone.

Jordyn Sava;Aditya Bardia, MD, MPH

February 6th 2025

FDA Oks Penpulimab for First-Line Non-Keratinizing Nasopharyngeal Carcinoma

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

The FDA has approved penpulimab with chemotherapy for first-line recurrent/metastatic non-keratinizing nasopharyngeal carcinoma and alone after prior treatment.

Jordyn Sava;Sanjay K. Juneja, MD

January 15th 2025

FDA Clears Phase 1 Study of TGW101 for Advanced Solid Tumor Treatment

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

SUNLIGHT Trial Defines CRC in the Refractory Setting

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum tolerated dose in up to 50 patients.

$SUNLIGHT Trial Defines CRC in the Refractory Setting$